These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 25481750)

  • 1. The T687G SNP in a P-glycoprotein gene of Fasciola hepatica is not associated with resistance to triclabendazole in two resistant Australian populations.
    Elliott TP; Spithill TW
    Mol Biochem Parasitol; 2014 Nov; 198(1):45-7. PubMed ID: 25481750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for high genetic diversity of NAD1 and COX1 mitochondrial haplotypes among triclabendazole resistant and susceptible populations and field isolates of Fasciola hepatica (liver fluke) in Australia.
    Elliott T; Muller A; Brockwell Y; Murphy N; Grillo V; Toet HM; Anderson G; Sangster N; Spithill TW
    Vet Parasitol; 2014 Feb; 200(1-2):90-6. PubMed ID: 24360656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standardisation of a coproantigen reduction test (CRT) protocol for the diagnosis of resistance to triclabendazole in Fasciola hepatica.
    Flanagan AM; Edgar HW; Forster F; Gordon A; Hanna RE; McCoy M; Brennan GP; Fairweather I
    Vet Parasitol; 2011 Feb; 176(1):34-42. PubMed ID: 21093156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An amino acid substitution in Fasciola hepatica P-glycoprotein from triclabendazole-resistant and triclabendazole-susceptible populations.
    Wilkinson R; Law CJ; Hoey EM; Fairweather I; Brennan GP; Trudgett A
    Mol Biochem Parasitol; 2012 Nov; 186(1):69-72. PubMed ID: 22982092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single amino acid substitution in isozyme GST mu in Triclabendazole resistant Fasciola hepatica (Sligo strain) can substantially influence the manifestation of anthelmintic resistance.
    Fernández V; Estein S; Ortiz P; Luchessi P; Solana V; Solana H
    Exp Parasitol; 2015 Dec; 159():274-9. PubMed ID: 26542261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clonal amplification of Fasciola hepatica in Galba truncatula: within and between isolate variation of triclabendazole-susceptible and -resistant clones.
    Hodgkinson JE; Cwiklinski K; Beesley N; Hartley C; Allen K; Williams DJL
    Parasit Vectors; 2018 Jun; 11(1):363. PubMed ID: 29941045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Threat of Triclabendazole Resistance in Fasciola hepatica.
    Kelley JM; Elliott TP; Beddoe T; Anderson G; Skuce P; Spithill TW
    Trends Parasitol; 2016 Jun; 32(6):458-469. PubMed ID: 27049013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased action of triclabendazole (TCBZ) in vitro against a TCBZ-resistant isolate of Fasciola hepatica following its co-incubation with the P-glycoprotein inhibitor, R(+)-verapamil.
    Savage J; Meaney M; Brennan GP; Hoey E; Trudgett A; Fairweather I
    Exp Parasitol; 2013 Nov; 135(3):642-53. PubMed ID: 24090567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disruption of vitellogenesis and spermatogenesis by triclabendazole (TCBZ) in a TCBZ-resistant isolate of Fasciola hepatica following incubation in vitro with a P-glycoprotein inhibitor.
    Savage J; Meaney M; Brennan GP; Hoey E; Trudgett A; Fairweather I
    Parasitology; 2014 Jul; 141(8):1064-79. PubMed ID: 24889697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fasciola hepatica: a comparative survey of adult fluke resistance to triclabendazole, nitroxynil and closantel on selected upland and lowland sheep farms in Northern Ireland using faecal egg counting, coproantigen ELISA testing and fluke histology.
    Hanna RE; McMahon C; Ellison S; Edgar HW; Kajugu PE; Gordon A; Irwin D; Barley JP; Malone FE; Brennan GP; Fairweather I
    Vet Parasitol; 2015 Jan; 207(1-2):34-43. PubMed ID: 25529143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro effects of triclabendazole (TCBZ) on the excretory-secretory products (ESP) of Fasciola spp parasites.
    Farahnak A; Golmohamdi T; Eshraghian M
    Acta Med Iran; 2012; 50(3):164-8. PubMed ID: 22418984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of putative markers of triclabendazole resistance by a genome-wide analysis of genetically recombinant Fasciola hepatica.
    Hodgkinson J; Cwiklinski K; Beesley NJ; Paterson S; Williams DJ
    Parasitology; 2013 Oct; 140(12):1523-33. PubMed ID: 23721579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative proteomic analysis of triclabendazole response in the liver fluke Fasciola hepatica.
    Chemale G; Perally S; LaCourse EJ; Prescott MC; Jones LM; Ward D; Meaney M; Hoey E; Brennan GP; Fairweather I; Trudgett A; Brophy PM
    J Proteome Res; 2010 Oct; 9(10):4940-51. PubMed ID: 20726552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fasciola hepatica: histological changes in the reproductive structures of triclabendazole (TCBZ)-sensitive and TCBZ-resistant flukes after treatment in vivo with TCBZ and the related benzimidazole derivative, Compound Alpha.
    Hanna RE; Edgar HW; McConnell S; Toner E; McConville M; Brennan GP; Devine C; Flanagan A; Halferty L; Meaney M; Shaw L; Moffett D; McCoy M; Fairweather I
    Vet Parasitol; 2010 Mar; 168(3-4):240-54. PubMed ID: 20053501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fasciola hepatica: histological demonstration of apoptosis in the reproductive organs of flukes of triclabendazole-sensitive and triclabendazole-resistant isolates, and in field-derived flukes from triclabendazole-treated hosts, using in situ hybridisation to visualise endonuclease-generated DNA strand breaks.
    Hanna RE; Forster FI; Brennan GP; Fairweather I
    Vet Parasitol; 2013 Jan; 191(3-4):240-51. PubMed ID: 23062689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High prevalence of fasciolosis and evaluation of drug efficacy against Fasciola hepatica in dairy cattle in the Maffra and Bairnsdale districts of Gippsland, Victoria, Australia.
    Elliott TP; Kelley JM; Rawlin G; Spithill TW
    Vet Parasitol; 2015 Apr; 209(1-2):117-24. PubMed ID: 25771931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance of Fasciola hepatica against Triclabendazole in cattle in Cajamarca (Peru): a clinical trial and an in vivo efficacy test in sheep.
    Ortiz P; Scarcella S; Cerna C; Rosales C; Cabrera M; Guzmán M; Lamenza P; Solana H
    Vet Parasitol; 2013 Jul; 195(1-2):118-21. PubMed ID: 23352107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potentiation of triclabendazole action in vivo against a triclabendazole-resistant isolate of Fasciola hepatica following its co-administration with the metabolic inhibitor, ketoconazole.
    Devine C; Brennan GP; Lanusse CE; Alvarez LI; Trudgett A; Hoey E; Fairweather I
    Vet Parasitol; 2012 Feb; 184(1):37-47. PubMed ID: 21872399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increase of gluthatione S-transferase, carboxyl esterase and carbonyl reductase in Fasciola hepatica recovered from triclabendazole treated sheep.
    Scarcella S; Solana MV; Fernandez V; Lamenza P; Ceballos L; Solana H
    Mol Biochem Parasitol; 2013 Oct; 191(2):63-5. PubMed ID: 24041589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased susceptibility of a triclabendazole (TCBZ)-resistant isolate of Fasciola hepatica to TCBZ following co-incubation in vitro with the P-glycoprotein inhibitor, R(+)-verapamil.
    Meaney M; Savage J; Brennan GP; Hoey E; Trudgett A; Fairweather I
    Parasitology; 2013 Sep; 140(10):1287-303. PubMed ID: 23756576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.